Shilpa Medicare Secures Regulatory Approval for Innovative Liver Treatment

Unknown Apr 02, 2026 3 Views

Shilpa Medicare Ltd has achieved a significant milestone in its pharmaceutical portfolio. The Central Drugs Standard Control Organisation (CDSCO) has recommended marketing authorization for the company's treatment for Non-Alcoholic Fatty Liver Disease (NAFLD). Additionally, Shilpa Medicare ha...

Stay Ahead – Explore Now! Sun Pharma’s Utreglutide Shows Promising Weight Loss and Metabolic Benefits in Obesity and MASLD Studies